Stuart W Peltz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6778312/publications.pdf

Version: 2024-02-01

25	4,332	361413	580821
papers	citations	20 h-index	25 g-index

25	25	25	4615
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PTC124 targets genetic disorders caused by nonsense mutations. Nature, 2007, 447, 87-91.	27.8	1,007
2	The cap-to-tail guide to mRNA turnover. Nature Reviews Molecular Cell Biology, 2001, 2, 237-246.	37.0	705
3	SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy. Science, 2014, 345, 688-693.	12.6	420
4	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
5	Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2014, 2, 539-547.	10.7	301
6	PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR -G542X nonsense allele in a CF mouse model. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2064-2069.	7.1	233
7	Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single- and Multiple-Dose Administration to Healthy Male and Female Adult Volunteers. Journal of Clinical Pharmacology, 2007, 47, 430-444.	2.0	218
8	The RNA Binding Protein Pub1 Modulates the Stability of Transcripts Containing Upstream Open Reading Frames. Cell, 2000, 101, 741-751.	28.9	164
9	Ataluren as an Agent for Therapeutic Nonsense Suppression. Annual Review of Medicine, 2013, 64, 407-425.	12.2	160
10	The Yeast hnRNP-like Protein Hrp1/Nab4 Marks a Transcript for Nonsense-Mediated mRNA Decay. Molecular Cell, 2000, 5, 489-499.	9.7	145
11	Nonsense-mediated mRNA decay in Saccharomyces cerevisiae. Gene, 2001, 274, 15-25.	2.2	124
12	A newly discovered function for RNase L in regulating translation termination. Nature Structural and Molecular Biology, 2005, 12, 505-512.	8.2	70
13	Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties. Molecular Cancer Therapeutics, 2019, 18, 3-16.	4.1	65
14	The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Research, 2021, 292, 198246.	2.2	53
15	Small molecule splicing modifiers with systemic HTT-lowering activity. Nature Communications, 2021, 12, 7299.	12.8	45
16	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
17	Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. Journal of Applied Physiology, 2010, 109, 901-905.	2.5	38
18	Nonsense suppression activity of PTC124 (ataluren). Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, E64; author reply E65.	7.1	36

#	Article	IF	Citations
19	The nucleoside analog clitocine is a potent and efficacious readthrough agent. Rna, 2017, 23, 567-577.	3.5	31
20	The minor gentamicin complex component, X2, is a potent premature stop codon readthrough molecule with therapeutic potential. PLoS ONE, 2018, 13, e0206158.	2.5	30
21	Identification of PTC725, an Orally Bioavailable Small Molecule That Selectively Targets the Hepatitis C Virus NS4B Protein. Antimicrobial Agents and Chemotherapy, 2013, 57, 3250-3261.	3.2	19
22	Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform. PLoS ONE, 2016, 11, e0168366.	2.5	18
23	Phase 1 Study of Safety, Tolerability, and Pharmacokinetics of PTC299, an Inhibitor of Stressâ€Regulated Protein Translation. Clinical Pharmacology in Drug Development, 2016, 5, 296-305.	1.6	16
24	Mining the GEMS â€“ a novel platform technology targeting post-transcriptional control mechanisms. Drug Discovery Today, 2007, 12, 553-560.	6.4	14
25	Targeting post-transcriptional control for drug discovery. RNA Biology, 2009, 6, 329-334.	3.1	14